Medical Device

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.

"Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally," said Marc N. Casper , chairman, president and chief executive officer, Thermo Fisher Scientific. "Investments in state-of-the-art manufacturing such as this ensure that our customers have reliable access to the high-quality materials and capabilities that have become vital for the production of these new lifesaving medicines and the patients in need."

The 67,000-square-foot facility, located on Thermo Fisher's Carlsbad campus, is part of an investment strategy to ensure customers can reliably meet growing global demand for cell and gene therapies and vaccines. With its fully integrated development, supply chain and manufacturing capabilities, which include viral vector services in Cambridge, Lexington and Plainville, Mass.. Alachua, Fla. and Gosselies and Seneffe, Belgium ; a new cell therapy manufacturing facility in Princeton, N.J.; and a new cryocenter in Weil am Rhein, Germany to support clinical trials, Thermo Fisher customers can quickly progress from discovery to clinical to patient impact.

Plasmid DNA is increasingly used as a therapeutic agent in gene therapies and certain vaccines. Its advantages, including weak immunogenicity, increased safety and ease of manufacture, have dramatically increased demand for materials and manufacturing capacity globally.

The expansion in Carlsbad also benefits the growing life sciences ecosystem in California , and Thermo Fisher will add more than 150 new roles as manufacturing scales. To celebrate the opening of the new facility, Thermo Fisher hosted a ribbon-cutting ceremony today with local government officials including U.S. Representatives Mike Levin and Scott Peters and Carlsbad City Mayor Matt Hall .

"This expansion in Carlsbad is exciting, bringing new jobs and revenue to our district, while also advancing San Diego County's reputation as a hub for innovation," said Rep. Levin, CA-49. "Their work helps tackle many of the world's greatest challenges and builds healthier, more sustainable communities."

Rep. Peters, CA-52 said, "I'm thrilled that this expansion will add jobs, advance medical services manufacturing capabilities in San Diego and California and further bolster our regions' leadership in scientific innovation."

"We're pleased that Thermo Fisher continues to expand its footprint in Carlsbad , and their investment will contribute greatly to our community's economic development and our reputation as a home to innovators who are improving health and medicine globally," said Carlsbad Mayor Matt Hall.

To learn more about Thermo Fisher's new cGMP Plasmid DNA manufacturing facility, please visit www.thermofisher.com/patheon .  Open positions can be found at jobs.thermofisher.com .

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Investments in state-of-the-art manufacturing ensure that Thermo Fisher cell and gene therapy customers have reliable access to the high-quality materials and capabilities that have become vital for the production of new therapies and vaccines.

Media Contact Information:
Ron O'Brien
Thermo Fisher Scientific

Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific

Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-opens-cgmp-plasmid-dna-manufacturing-facility-in-carlsbad-california-301334287.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology

Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura's CryoSPARC Live, that is designed to integrate with Thermo Fisher's Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live , will be offered as a subscription.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Viemed Healthcare Announces Second Quarter 2022 Financial Results

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2022.

Operational highlights (all dollar amounts are USD):

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7 th . Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Viemed Announces Executive Additions to Lead Acquisition Growth

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced the additions of Michael Freeman as Chief Business Development Officer and Jeremy Trahan as Chief Legal Officer and Executive Vice President of Acquisitions and Strategic Transactions. Prior to joining the team at Viemed, Freeman and Trahan were executives at LHC Group, Inc ("LHC")(NASDAQ:LHCG), where together they directed and were integrally involved in over 100 transactions valued at approximately $1.9 billion, collectively.

"We are thrilled to expand our team of extremely talented executives by welcoming Michael and Jeremy," said Casey Hoyt, Viemed Chief Executive Officer. "Together, they have a proven track record of success and their leadership and experience will support a strong acquisition infrastructure within our organization. I am confident that they will play a critical role in the next major chapter of our organizational growth."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
ALR Technologies Announces First Shipment of GluCurve Pet CGMs Expected in October and Update on the Manufacturing Agreement

ALR Technologies Announces First Shipment of GluCurve Pet CGMs Expected in October and Update on the Manufacturing Agreement

ALR Technologies SG Pte. Ltd ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, announces the Company has received manufacturing approval from Infinovo Medical Co., Ltd. ("Infinovo") to place the first purchase order ("PO") for the GluCurve Pet CGM with an expected delivery date of October 2022. Furthermore, the manufacturing and supply agreement with Infinovo was subject to certain closing conditions, including entering into a binding sales and distribution agreement for the GluCurve Pet CGM by July 31, 2022. Both parties agreed to let that agreement terminate and are now working on completing a new agreement under the same terms, extending the closing condition for ALRT to enter into a binding sales and distribution agreement for GluCurve to August 31, 2022.

"We have agreed in principle on the key terms for a global sales and distribution agreement with a leading animal health company," commented Joe Stern, Head of Animal Health at ALRT. "The last step in their due diligence process is to evaluate the GluCurve Pet CGM internally by using it on their own sample of customers and their respective pets. This step is taking longer than we initially projected due to scheduling delays. After discussing the delays with Infinovo we agreed it would be in both parties' best interest to complete a new contract extending the date of the closing condition for a sales and distribution agreement date to August 31, 2022. Based on our non-inferiority study results earlier this year, we do not expect this delay to alter our commercialization schedule and will provide further updates on timing and details of the initial launch upon the execution of the global sales and distribution agreement."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

-- Company to Appeal Expected Court Decision on Certain XIFAXAN® Patents –

Bausch Health Companies Inc. (NYSETSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×